Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

171 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-04-04

Study Completion Date

2019-05-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB as potential diagnostic and prognostic biomarkers in ovarian carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

New Serum Biomarkers for Monitoring Early Diagnosis of Ovarian Cancer Recurrence

NCT05410028

Ovarian Cancer

RECRUITING

Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer

NCT01150682

Endometrial Cancer

UNKNOWN

UMCC 003 Cancer-Related Protein Biomarkers in Blood and Tumor Tissue of Patients With Cancer

NCT00900094

Breast Cancer Colorectal Cancer Esophageal Cancer +4 more

COMPLETED

Biomarkers in Blood and Tissue Samples From Patients With Uterine Cancer

NCT01344837

Endometrial Serous Adenocarcinoma Stage I Uterine Corpus Cancer Stage II Uterine Corpus Cancer +2 more

COMPLETED

Biomarkers in Tissue Samples From Patients With Stage I or Stage III Endometrial Cancer

NCT01119573

Endometrial Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Neoplasms Ovarian Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Patients with ovarian carcinoma

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of patients with a presumed diagnosis of ovarian carcinoma will be determined prior to surgery.

TFF3, SFRP4, Romo1, NFKB

Intervention Type DIAGNOSTIC_TEST

Blood samples of all participants will be collected.

Control group

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women without any adnexal mass nor malignancy will be determined to compare with other groups.

TFF3, SFRP4, Romo1, NFKB

Intervention Type DIAGNOSTIC_TEST

Blood samples of all participants will be collected.

Benign adnexal mass

Serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB of women with an adnexal mass will be determined to compare with other groups.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TFF3, SFRP4, Romo1, NFKB

Blood samples of all participants will be collected.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary diagnosis of epithelial ovarian carcinoma.

Exclusion Criteria

* Patients with recurrence.
* Patients who received neoadjuvant chemotherapy or radiotherapy
* Presence of any secondary malignancy

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ilker Kahramanoglu

MD, Gynecologic Oncology Fellow

Responsibility Role SPONSOR_INVESTIGATOR